PT-141 10 mg
Educational recon guide for a 10 mg PT-141 (bremelanotide) research vial and as-needed unit mapping. Research use only — not Vyleesi autoinjectors.
Vial
10 mg
Your BAC water
2 mL
Concentration
5.00 mg/mL
Per unit
~50.0 mcg
Frequency
As needed before anticipated sexual activity (approved label: ≥45 min prior; ≤1 dose/24 h; ≤8 doses/month)
Route
Subcutaneous (abdomen or thigh on approved product)
Live reconstitution calculator
Defaults match this guide (10 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
Quick-select common research doses (includes 2.5 / 7.5 for dual-agonist ladders) or type any mg / mcg value.
Quick select (mg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
20 units
Volume
0.200 mL
Doses per vial
10
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 20 u
Fill one 30-unit U-100 syringe to about 20 units (0.200 mL).
Weekly research phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 5.00 mg/mL · 50.0 mcg/unit).
Standard titration
Approved bremelanotide (Vyleesi) is 1.75 mg SC as needed, at least 45 minutes before activity, max one dose per 24 hours and max 8 doses per month. Research-market vials are not the autoinjector product; some secondary charts discuss lower test amounts (~0.5–1 mg) for tolerability.
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| As-needed · 1.0 mg (tolerability step) | 1 mg1,000 mcg | 20 u | 0.20 mLLower educational amount some use before full 1.75 mg |
| As-needed · 1.75 mg (approved-style) | 1.75 mg1,750 mcg | 35 u | 0.35 mLMatches Vyleesi labeled single dose (research vial math only) |
Advanced / higher-end
Faster escalation discussed in research communities — not a clinical recommendation
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Higher community · 2.0 mg | 2 mg2,000 mcg | 40 u | 0.40 mLAbove approved single dose — nausea/BP risk discussions increase |
Supplies planner
Using the guide’s phase ladder (1 mg → 1.75 mg weekly (phase ladder)) over a 8-week schedule. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 5.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
8-week schedule
PT-141 10 mg vials
2 vials
~11 mg mg total peptide over this 8-week schedule at 1 mg → 1.75 mg weekly (phase ladder). Each vial holds 10 mg.
Bacteriostatic water
2 × 3 mL or 1 × 10 mL
2 mL BAC per vial × 2 vials = 4.0 mL total. Buy as 2× 3 mL bottles or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
8+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~20 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 10 mg PT-141 vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "5.0 mg/mL — 2 mL BAC").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·Melanocortin agonist (related family to Melanotan peptides) acting centrally on desire pathways.
- ·Approved product limits: no more than 1 dose/24 h and 8 doses/month — BP and nausea driven.
- ·Research powders ≠ Vyleesi pens.
- ·Research use only.
Research context & considerations
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women. Research-market PT-141 vials are a separate unregulated channel and are also discussed off-label in men in clinics/forums.
- ·Nausea is very common; temporary blood-pressure increases can occur.
- ·Focal hyperpigmentation reported with frequent use.
- ·Not for cardiovascular risk patients without clinical context.
- ·Research vials are not a substitute for prescribed Vyleesi.
- ·Pregnancy out of scope.
Catalog match
PT141
10mg x 10 vials · from $25